OncoMatch/Clinical Trials/NCT03379909
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
Is NCT03379909 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metformin for superficial bladder cancer.
Treatment: Metformin — A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Grade: g1g2
Performance status
ECOG-WHO 0–2
Prior therapy
Cannot have received: intravesical chemotherapy
Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.
Cannot have received: intravesical immunotherapy
Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.
Cannot have received: anti-cancer therapy
Patients that are currently receiving other anti-cancer therapy.
Lab requirements
Kidney function
egfr >50 ml/min/1.73m2 according to ckd-epi
Liver function
bilirubin <1.5 times upper limit of normal, alat or asat <2.5 the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify